Development of potent and selective tissue transglutaminase inhibitors

Eduard Badarau, Zhuo Wang, Dan L. Rathbone, Andrea Costanzi, Thomas Thibault, Colin E. Murdoch, Said El Alaoui, Milda Bartkeviciute, Martin Griffin (Lead / Corresponding author)

Research output: Contribution to journalArticlepeer-review

35 Citations (Scopus)


Potent-selective peptidomimetic inhibitors of tissue transglutaminase (TG2) were developed through a combination of protein-ligand docking and molecular dynamic techniques. Derivatives of these inhibitors were made with the aim of specific TG2 targeting to the intra- and extracellular space. A cell-permeable fluorescently labeled derivative enabled detection of in situ cellular TG2 activity in human umbilical cord endothelial cells and TG2-transduced NIH3T3 cells, which could be enhanced by treatment of cells with ionomycin. Reaction of TG2 with this fluorescent inhibitor in NIH3T3 cells resulted in loss of binding of TG2 to cell surface syndecan-4 and inhibition of translocation of the enzyme into the extracellular matrix, with a parallel reduction in fibronectin deposition. In human umbilical cord endothelial cells, this same fluorescent inhibitor also demonstrated a reduction in fibronectin deposition, cell motility, and cord formation in Matrigel. Use of the same inhibitor in a mouse model of hypertensive nephrosclerosis showed over a 40% reduction in collagen deposition.
Original languageEnglish
Pages (from-to)1347-1361
Number of pages15
JournalChemistry & Biology
Issue number10
Early online date9 Oct 2015
Publication statusPublished - 22 Oct 2015


  • irreversible tissue transglutaminase inhibitors


Dive into the research topics of 'Development of potent and selective tissue transglutaminase inhibitors'. Together they form a unique fingerprint.

Cite this